Abstracts tagged "inflammation and systemic lupus erythematosus (SLE)"

Abstract Number: 760 • 2018 ACR/ARHP Annual Meeting
Diagnosing SLE Arthritis with Dynamic Diffuse Optical Spectroscopy
George Danias¹, Youngwan Kim², Alessandro Marone³, Kayla Neville¹, Andrea Frantz¹, Teja Kapoor⁴, Laura Geraldino-Pardilla¹, Ioannis Kymissis², Andreas Hielscher^2,3,5 and Anca Askanase¹, ¹Rheumatology, Columbia University Medical Center, New York, NY, ²Electrical Engineering, Columbia University, New York, NY, ³Biomedical Engineering, Columbia University, New York, NY, ⁴Rheumatology, Columbia University, College of Physicians & Surgeons, New York, NY, ⁵Radiology, Columbia University Medical Center, New York, NY
Background/Purpose: SLE arthritis is difficult to evaluate because of the sometimes-evanescent nature of the symptoms and limitations of physical exams and imaging studies. Dynamic diffuse…
Abstract Number: 934 • 2018 ACR/ARHP Annual Meeting
HIV Protease Inhibitors Cure Lupus-Prone Mice and Prevent T Helper 17 Cell-Driven Inflammation By Inhibiting CD95-Non-Apoptotic Signaling Pathway
Manon Charrier¹, Amanda Poissonnier², Daniel Best², Jean-Philippe Guégan², Nicolas Levoin³, Raphael Pineau², Florence Jouan², Ha Thanh Nguyen², Lucie Morere², Sophie Martin², Melissa Thomas², Estibaliz Lazaro¹, Christophe Richez¹, Isabelle Douchet¹, Thomas Ducret⁴, Pierre Van de Weghe², Patrick Blanco¹, Mickael Jean², Pierre Vacher⁵ and Patrick Legembre², ¹UMR CNRS 5164 - Immunoconcept, Bordeaux, France, ²Chemistry Oncogenesis Stress Signaling, INSERM UMR 1242 Rennes University, Rennes, France, ³Bioprojet Biotech, Saint-Grégoire, France, ⁴INSERM U1218, Bordeaux University, Bordeaux, France, ⁵Actions for onCogenesis understanding and Target Identification in ONcology, INSERM U1218, Bordeaux University, Bordeaux, France
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by loss of tolerance to nuclear components; this results in production of autoantibodies, immune…
Abstract Number: 819 • 2015 ACR/ARHP Annual Meeting
Upregulation of Complement C3 and Alpha-2-Macroglobulin in Cerebrospinal Fluid of Neuropsychiatric Systemic Lupus Erythematosus
Tomoyuki Asano¹, Shuzo Sato¹, Hiroko Kobayashi¹, Yoshinobu Kariya², Hiromi Ito², Kyoka Hoshi², Akioh Yoshihara³, Yoshikazu Ugawa³, Minoru Takahashi⁴, Hideharu Sekine⁴, Shunsei Hirohata⁵, Hiroshi Watanabe¹, Hiromasa Ohira¹ and Yasuhiro Hashimoto², ¹Gastroenterology and Rheumatology, Fukushima Medical University School of Medicine, Fukushima, Japan, ²Biochemistry, Fukushima Medical University School of Medicine, Fukushima, Japan, ³Neurology, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁴Immunology, Fukushima Medical University School of Medicine, Fukushima, Japan, ⁵Rheumatology and Infectious Diseases, Kitasato University School of Medicine, Kanagawa, Japan
Background/Purpose: Various autoantibodies have been identified in cerebrospinal fluids (CSF) of neuropsychiatric systemic lupus erythematosus (NPSLE). They are supposed to form immune complex with complement…
Abstract Number: 1787 • 2015 ACR/ARHP Annual Meeting
Innate Immunity, Arterial Inflammation and Vascular Stiffness in Patients with Systemic Lupus Erythematosus
Monica Purmalek¹, Simantini Sakhardande¹, Yenealem Temesgen-Oyelakin², Alice Fike³, Taufiq Salahuddin⁴, Balaji Natarajan⁴, Zerai Manna², Elizabeth Joyal², Sarfaraz Hasni², Nehal N. Mehta⁴ and Mariana J. Kaplan¹, ¹Systemic Autoimmunity Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ³Office of the Clinical Director, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁴NHLBI, National Institutes of Health, Bethesda, MD
Background/Purpose: Patients with systemic lupus erythematosus (SLE) show a striking increase in risk of atherosclerotic cardiovascular disease (CVD) not explained by Framingham risk, compared to…
Abstract Number: 1630 • 2014 ACR/ARHP Annual Meeting
A Novel NMR Biomarker of Inflammation (GlycA) Is Elevated in Systemic Lupus Erythematosus
Cecilia P. Chung¹, Michelle J. Ormseth^2,3, Annette M. Oeser³, Joseph F. Solus^3,4, Margery A. Connelly⁵, James D. Otvos⁶ and C. Michael Stein^3,7, ¹Medicine, Vanderbilt University, Nashville, TN, ²Rheumatology, Vanderbilt Medical Center, Nashville, TN, ³Vanderbilt University, Nashville, TN, ⁴Medicine, Vanderbilt Medical Center, Nashville, TN, ⁵LipoScience, Inc., Raleigh, NC, ⁶LipoScience Inc., Raleigh, NC, ⁷Div of Clinical Pharmacology, Vanderbilt Univ School of Med, Nashville, TN
Background/Purpose: Nuclear magnetic resonance (NMR) spectra from samples analyzed for lipoproteins also contain a peak (termed GlycA) resulting from glycosylated proteins. GlycA is not only…
Abstract Number: 1767 • 2013 ACR/ARHP Annual Meeting
Gender, Race, and Soluble Mediators Distinguish Blood Relatives Who Develop Incomplete Lupus Or Classified SLE In The Lupus Autoimmunity In Relatives (LAUREL) Study
Melissa E. Munroe¹, Kendra A. Young², Jill M. Norris², Joel M. Guthridge³, Diane L. Kamen⁴, Timothy B. Niewold⁵, Gary S. Gilkeson⁴, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley^9,10 and Judith A. James^11,12, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ¹⁰US Department of Veterans Affairs Medical Center, Cincinnati, OH, ¹¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹²College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and identify individuals for prevention trials. Healthy blood relatives (FDRs) of lupus…
Abstract Number: 635 • 2013 ACR/ARHP Annual Meeting
Multiple Altered Soluble Inflammatory Mediators Correlate With Disease Activity and Mark Impending Disease Flare In European-American Lupus Patients
Melissa E. Munroe¹, Jourdan R. Anderson², Krista M. Bean³, Joan T. Merrill⁴, Joel M. Guthridge³, Virginia C. Roberts³, Linda F. Thompson^5,6 and Judith A. James^4,7, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁵University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁶Immunobiology and Cancer, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷College of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: SLE is a waxing and waning disease characterized by immune dysregulation, major organ involvement, and disease flares. Identifying mechanistic mediators of altered disease activity…
Abstract Number: 2537 • 2013 ACR/ARHP Annual Meeting
Inactive Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disease characterized by a chronic inflammation associated with worse cardiovascular outcome. Although a few studies have…
Abstract Number: 2545 • 2013 ACR/ARHP Annual Meeting
Active Systemic Lupus Erythematosus: Cytokines and Soluble Tumor Necrosis Factor Receptors Response To Moderate/Intense Exercise
Luiz A. Perandini¹, Diego Sales-de-Oliveira¹, Suzana B.V. Mello², Niels O Camara³, Fernanda R. Lima¹, Eduardo F. Borba², Eloisa Bonfa², Ana Lucia Sá-Pinto¹, Hamilton Roschel⁴ and Bruno Gualano⁵, ¹University of Sao Paulo, Rheumatology Division, Sao Paulo, Brazil, ²University of Sao Paulo, Rheumatology Division, São Paulo, Brazil, ³Department of Immunology, Institute of Biomedical Sciences, University of Sao Paulo, Sao Paulo, Brazil, ⁴Universidade de São Paulo, Faculdade de Educação Física e Esporte, São Paulo, Brazil, ⁵University of Sao Paulo, School of Physical Education and Sport, Sao Paulo, Brazil
Background/Purpose: Systemic lupus erythematosus (SLE) is a rheumatic autoimmune condition characterized by altered lipoprotein profile, physical dysfunction and increased risk of cardiovascular disease. Exercise is,…
Abstract Number: 1443 • 2012 ACR/ARHP Annual Meeting
Caspase-1 Modulates Endothelial Dysfunction and Vascular Repair in Murine Lupus
J. Michelle Kahlenberg¹, Wenpu Zhao², Srilakshmi Yalavarthi² and Mariana J. Kaplan³, ¹Internal Medicine, Division of Rheumatology, University of Michigan, Ann Arbor, MI, ²University of Michigan Rheumatology, Ann Arbor, MI, ³Systemic Autoimmunity Branch, National Institutes of Health/NIAMS, Bethesda, MD
Background/Purpose: Premature cardiovascular disease (CVD) represents a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE). We recently proposed that type I interferon…
Abstract Number: 623 • 2012 ACR/ARHP Annual Meeting
Endothelial Microparticles As a Biomarker for Endothelial Dysfunction in Active Systemic Lupus Erythematosus
Ben Parker¹, Awal Zaki², M. Yvonne Alexander³ and Ian N. Bruce⁴, ¹Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit,, Manchester, United Kingdom, ²Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit, Manchester, United Kingdom, ³Healthcare Science Research Institute, Faculty of Science and Engineering, Healthcare Science Research Institute, Manchester Metropolitan University, Manchester, United Kingdom, ⁴Manchester Academic Health Science Centre, Arthritis Research UK Epidemiology Unit and NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is associated with an increased risk of clinical and subclinical cardiovascular disease (CVD) including endothelial dysfunction, in part due to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].